Skip to Content
Merck
CN
All Photos(1)

Documents

Safety Information

A6476

Sigma-Aldrich

ABT-418 hydrochloride

powder, ≥98% (HPLC)

Sign Into View Organizational & Contract Pricing

Synonym(s):
3-Methyl-5-[(2S)-1-methyl-2-pyrrolidinyl]isoxazole hydrochloride
Empirical Formula (Hill Notation):
C9H14N2O · HCl
CAS Number:
Molecular Weight:
202.68
MDL number:
UNSPSC Code:
51111800
PubChem Substance ID:
NACRES:
NA.77

Quality Level

Assay

≥98% (HPLC)

form

powder

storage condition

desiccated

solubility

H2O: soluble 15 mg/mL

originator

Abbott

SMILES string

Cl.CN1CCC[C@H]1c2cc(C)no2

InChI

1S/C9H14N2O.ClH/c1-7-6-9(12-10-7)8-4-3-5-11(8)2;/h6,8H,3-5H2,1-2H3;1H/t8-;/m0./s1

InChI key

VOXHERKWAIEJQF-QRPNPIFTSA-N

General description

ABT-418 is an α4β2 agonist of nicotinic receptors.

Application

ABT-418 [(S)-3-methyl-5-(1 methyl-2-pyrrolidinyl)isoxazole hydrochloride] is a novel neuronal nicotinic acetylcholine receptor (nAChR) ligand with cognitive enhancing and anxiolytic-like activity 3- to 10-fold more potent than (-)-nicotine in rodents. ABT-418 hydrochloride has been used to study new therapeutic approaches for the treatment of Alzheimer′s disease.
ABT-418 hydrochloride has been used as a nicotinic acetylcholine receptor (nAChR) agonist to test its effect on spatial memory improvement in attention deficit hyperactivity disorder (ADHD) rat model

Biochem/physiol Actions

Neuronal nicotinic acetylcholine receptor agonist with cognition enhancing and anxiolytic activities.

Features and Benefits

This compound is featured on the Acetylcholine Receptors (Nicotinic) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Abbott. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Legal Information

Subject to U.S. Patent No. 5409946 and sold under license from Abbott Laboratories.

Pictograms

Skull and crossbones

Signal Word

Danger

Hazard Statements

Hazard Classifications

Acute Tox. 2 Dermal - Acute Tox. 2 Inhalation - Acute Tox. 2 Oral

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

新产品

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

J D Brioni et al.
The Journal of pharmacology and experimental therapeutics, 271(1), 353-361 (1994-10-01)
The hydrochloride salt of (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT-418), a potent activator of select subtypes of neuronal nicotinic acetylcholine receptors enhanced retention in memory tests and induced anxiolytic-like effects in mice in the elevated plus maze. In the present studies in rats
J D Brioni et al.
Psychopharmacology, 119(4), 368-375 (1995-06-01)
Previous studies have established that ABT-418 [(S)-3-methyl-5-(1 methyl-2-pyrrolidinyl)isoxazole hydrochloride] is a novel neuronal nicotinic acetylcholine receptor (nAChR) ligand with cognitive enhancing and anxiolytic-like activity 3- to 10-fold more potent than (-)-nicotine in rodents. A series of experiments was conducted to
R Nikolov
Drug news & perspectives, 11(4), 248-255 (2004-12-24)
The 5th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy focused on new therapeutic approaches for the treatment of Alzheimer 's disease (AD) based on the latest basic science data. The two major pharmacological principles of cholinergic therapy are 1)
Tianyou Guo et al.
Neuroscience letters, 528(1), 11-15 (2012-09-19)
Impaired learning performance in scholastic settings is a characteristic of attention deficit hyperactivity disorder (ADHD). Our present study compares the effect of a nicotinic acetylcholine receptor (nAChR) agonist, ABT-418, and methylphenidate (MPH) on spatial memory in spontaneously hypertensive rats (SHRs)
Nikolaos Pitsikas
Behavioural brain research, 393, 112778-112778 (2020-06-25)
Several lines of evidence indicate that anesthetic doses of the non-competitive N-methyl-D-aspartate receptor antagonist ketamine disrupt memory functions in rodents. The mechanism by which anesthetic ketamine produces its adverse behavioural effects is not yet clarified. The implication of nicotinic acetylcholine

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service